Table 2. Overview of all results including the corresponding significances.

	SW-684		SW-982		SW-1353
Method	ALDH1high	ALDH1low	ALDH1high	ALDH1low	ALDH1high	ALDH1low
% ALDH1high cells	1.77±0.9		2.23±1.0		2.69±1.3
Aldefluor® Assay
% ALDH1high cells	41.7±18.6		52.5±8.7		31.7±11.1
Repopulation Assay	p = 0.0039		p = 4.4E-7		p = 0.0025
expression (%)	67.17%	32.83%	55.34%	44.66%	72.57%	27.43%
ALDH1 western blot
Ki-67 positivity	0.85±0.17	0.38±0.05	0.59±0.31	0.35±0,27	0.98±0.01	0.18±0.15
Quantitation IHC
CFE %	4.95±2.59	5.16±2.25	19.0±3.42	15.8±7.66	10.5±2.74	6.5±2.41
colony formation assay					p = 0.0047
c-Myc	1.72±1.44	1.33±1.04	1.52±0.69	0.99±0.40	2.33±1.77	0.82±0.33
relative gene expression
β-catenin	0.98±0.82	0.87±0.87	0.41±0.06	0.81±0.18	1.16±0.13	0.95±0.37
relative gene expression
SOX-2	25.2±19.4	9.66±2.77	1.96±1.29	1.02±0.59	4.37±3.83	39.82±28.61
relative gene expression
ABCG2/BCRP1	2.42±1.56	1.05±0.15	2.28±0.78	1.15±0.29	4.38±0.73	1.76±0.23
relative gene expression	p = 0.0143		p = 0.0047		p = 0.0227
ABCA2	1.04±0.34	0.94±0.32	3.42±1.37	1.32±0.25	1.88±0.41	0.62±0.17
relative gene expression
ABCB1/MDR1	1.66±0.61	1.14±0.28	2.25±1.03	1.08±0.27	11.15±2.55	1.52±0.22
relative gene expression					p = 0.0302
doxorubicin IC50	1.5 µM	1.4 µM	1.8 µM	0.9 µM	1.1 µM	0.7 µM
drug sensitivity
epirubicin IC50	2.2 µM	2.0 µM	1.3 µM	0.5 µM	1.5 µM	0.7 µM
drug sensitivity
cisplatin IC50	25.7 µM	24.9 µM	23.7 µM	18.8 µM	30.7 µM	26.2 µM
drug sensitivity